Illumina, Inc. (NASDAQ:ILMN)‘s stock had its “overweight” rating restated by investment analysts at Piper Jaffray Companies in a research report issued on Monday, October 9th. They currently have a $226.00 target price on the life sciences company’s stock, up from their prior target price of $202.00. Piper Jaffray Companies’ price objective points to a potential upside of 7.68% from the company’s current price.
Several other research analysts have also recently weighed in on the stock. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $200.00 price objective on shares of Illumina in a report on Tuesday, September 26th. Vetr raised shares of Illumina from a “hold” rating to a “buy” rating and set a $217.50 price objective for the company in a report on Tuesday, September 19th. Argus boosted their price objective on shares of Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a report on Wednesday, September 13th. Leerink Swann reissued an “outperform” rating and set a $225.00 price objective (up from $207.00) on shares of Illumina in a report on Tuesday, September 12th. Finally, BidaskClub cut shares of Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $190.50.
Illumina (NASDAQ ILMN) opened at 209.88 on Monday. Illumina has a 1-year low of $119.37 and a 1-year high of $214.34. The stock has a 50 day moving average price of $205.74 and a 200-day moving average price of $186.97. The firm has a market cap of $30.64 billion, a P/E ratio of 42.11 and a beta of 0.76.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662.00 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the previous year, the company earned $0.86 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Illumina will post $3.65 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/illumina-inc-ilmn-earns-overweight-rating-from-piper-jaffray-companies/1704242.html.
In other news, EVP Omead Ostadan sold 1,671 shares of the stock in a transaction on Monday, August 7th. The shares were sold at an average price of $195.26, for a total value of $326,279.46. Following the sale, the executive vice president now owns 24,571 shares of the company’s stock, valued at $4,797,733.46. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Oene Mark Van sold 1,250 shares of the stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $207.21, for a total transaction of $259,012.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 182,766 shares of company stock worth $36,411,334. 1.60% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in ILMN. Municipal Employees Retirement System of Michigan raised its stake in shares of Illumina by 1.5% in the first quarter. Municipal Employees Retirement System of Michigan now owns 4,740 shares of the life sciences company’s stock valued at $809,000 after acquiring an additional 70 shares during the period. Teachers Advisors LLC grew its holdings in shares of Illumina by 60.7% in the first quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock worth $65,577,000 after purchasing an additional 145,231 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Illumina by 83.9% in the first quarter. Bellevue Group AG now owns 98,944 shares of the life sciences company’s stock worth $16,884,000 after purchasing an additional 45,144 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Illumina by 3.9% in the first quarter. Legal & General Group Plc now owns 651,314 shares of the life sciences company’s stock worth $111,142,000 after purchasing an additional 24,613 shares during the last quarter. Finally, Utah Retirement Systems grew its holdings in shares of Illumina by 0.4% in the first quarter. Utah Retirement Systems now owns 26,790 shares of the life sciences company’s stock worth $4,572,000 after purchasing an additional 100 shares during the last quarter. 93.32% of the stock is currently owned by institutional investors and hedge funds.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with our FREE daily email newsletter.